Liminatus Pharma, Inc.
PublicLiminatus Pharma, Inc. is now publicly traded
The data on this page reflects Liminatus Pharma, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Warrant Exercise
Jun 18, 2026
Total Funding Raised
$1.86M
Company Overview
Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company that develops novel immune-modulating cancer therapies, including CD47-blockade antibodies and cancer vaccines.
AI Layer
Application
Keywords
immuno-oncologymonoclonal antibodyCD47-blockadecancer immunotherapyCAR-T therapysolid tumorbiopharmaceuticalprecision medicineclinical-stage biotechdrug discoverycancer vaccinebiomarkernext-gen oncologybiotech startup
Liminatus Pharma, Inc. Comparables
Compare Liminatus Pharma, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InnoBation Bio | 86% | |
| Link Cell Therapies | 69% | |
Liminatus Pharma, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Warrant Exercise | Jun 18, 2026 |
Liminatus Pharma, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersFULLERTON
Employee Range4
Year Founded2018
Last FundingJun 18, 2026
See something wrong or outdated?